Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
MEK inhibition in breast cancer is associated with increased tumour infiltrating lymphocytes (TILs), however, MAPK activity is required for T cells function. Here the authors show that TILs activity following MEK inhibition can be enhanced by agonist immunotherapy resulting in synergic therapeutic e...
Guardado en:
Autores principales: | Sathana Dushyanthen, Zhi Ling Teo, Franco Caramia, Peter Savas, Christopher P. Mintoff, Balaji Virassamy, Melissa A. Henderson, Stephen J. Luen, Mariam Mansour, Michael H. Kershaw, Joseph A. Trapani, Paul J. Neeson, Roberto Salgado, Grant A. McArthur, Justin M. Balko, Paul A. Beavis, Phillip K. Darcy, Sherene Loi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9dca7cf8454b4a3b9462fc4df89bf7de |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
por: Shahneen Sandhu, et al.
Publicado: (2021) -
Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor
por: Sumanth Nagabushan, et al.
Publicado: (2021) -
Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma
por: H. Halse, et al.
Publicado: (2018) -
BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
por: Stefanie Hoyer, et al.
Publicado: (2021) -
A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition.
por: Neda Bagheri, et al.
Publicado: (2011)